Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | MLNR | O43193 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998237 | 0.89 | MLNR (0.48) | GPR119MLNRKDM4ERORCTGFBR1 | |
| SCHEMBL2000792 | 0.89 | KDM4E (0.48) | GPR119MLNRKDM4ETGFBR1 | |
| SCHEMBL1995580 | 0.88 | MLNR (0.64) | GPR119MLNRRORCTGFBR1 | |
| SCHEMBL2849498 | 0.88 | MLNR (0.51) | MLNRKDM4ERORCCHRM4CCR1 | |
| SCHEMBL2003105 | 0.87 | MLNR (0.52) | GPR119MLNRKDM4ERORCTGFBR1 | |
| SCHEMBL1999376 | 0.86 | MLNR (0.54) | GPR119MLNRKDM4ETGFBR1 | |
| SCHEMBL1995197 | 0.86 | MLNR (0.63) | GPR119MLNRTGFBR1CCR1 | |
| SCHEMBL1998342 | 0.86 | MLNR (0.49) | GPR119MLNRCCR1 | |
| SCHEMBL2003276 | 0.86 | MLNR (0.49) | GPR119MLNRCCR1 | |
| SCHEMBL1997571 | 0.84 | GPR119 (0.48) | GPR119CHRM4CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| WO-2009068552-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | GPR119 4/4885MLNR 12/4885KDM4E 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.